Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates

Clicks: 1
ID: 319985
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #109 of 331 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 331 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Antibody-drug conjugates (ADCs) have substantially improved outcomes for patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Whether these survival gains have translated equitably across racial and ethnic groups remains unclear despite persistent disparities in breast cancer outcomes. METHODS: We conducted a retrospective cohort study using de-identified electronic health record data from the TriNetX Research Network (2010 to 2024). Adults with HER2+ MBC treated with trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) were included. Overall survival (OS) was estimated using Kaplan-Meier methods and compared across racial and ethnic groups. Multivariable Cox models adjusted for age, body mass index, chronic obstructive pulmonary disease, hypertension, diabetes mellitus, and prior lines of therapy. RESULTS: The cohort included 7,462 patients with HER2+ MBC: 5,072 non-Hispanic White (NHW) (68%), 1,193 Black (16%), 746 Hispanic (10%), and 298 Asian (4%). Five-year OS was highest among Asian (89.9%) and Hispanic (86.3%) patients, followed by NHW (84.0%) and Black patients (80.3%) (P < .001). Compared with NHW patients, Black patients experienced significantly worse OS (adjusted HR, 1.22; 95% CI, 1.03 to 1.45; P=.03). Survival differences among Asian and Hispanic patients were not significant after multivariable adjustment. CONCLUSIONS: Among patients with HER2+ MBC treated with HER2-directed ADCs, Black patients experienced persistently inferior survival despite receipt of effective therapies. These findings highlight ongoing inequities and underscore the need for interventions to ensure equitable translation of therapeutic advances across all populations.
Reference Key
openalex_W7167634584 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zunairah Shah, Lan Lei, Rahul Thakur, Ajinkya Buradkar, Malak Alharbi, Mulham Ombada, Song Yao, Alfredo Chua, Han Yu, S Badve, Thaer Khoury, Anant Madabhushi, Ujjwal Baid, Kevin Kalinsky, S. Kabraji, Shipra Gandhi
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag223
URL
https://doi.org/10.1093/jnci/djag223
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.